Clinical Trial Search

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants

Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…

Primary: Response Rate — 0; 1; 3; 11 Participants

Primary: Number of Subjects With Study Related Adverse Events. — 59 Participants

Primary: Engraftment — 15; 15 days

Primary: Number of Participants With Complete Response (CR) — 14 participants

Primary: Number of Patients Who Obtain Partial Response/Complete Remission — 1; 5 Participants

Primary: Documenting Adverse Events (AEs), Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs) (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters…

Primary: Progression-free Survival (PFS) — 981.0; 1212.0 Days — p=<.0001

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: Overall Survival at 1 Year — 90 percentage of participants

Primary: Rate of Successful Manufacture of CD22 CAR T Cells — 94; 100; 100 Percentage

Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events

Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Grades of Toxicity by Type of Toxicity — 2; 2; 1; 1 toxicities

Primary: Number of Confirmed Responses (Complete or Partial Response Noted as the Objective Status for a Duration of at Least 2 Months) at 6 Months — 31 Participants

Primary: Percentage of Enrolled Participants Who Actually Get Treated — 76.9 percentage of participants

Primary: Complete Remission Rate: Percentage of Participants With Complete Remission (CR) — 85 percentage of participants

Primary: Overall Response Rate — 11; 2 Participants

Primary: Grade ≥ 3 Stomatitis — 4; 6; 41; 34 participants

Primary: Death Within 8 Weeks of the Study Cell Infusion Thought to be Definitely or Probably Related to Chimeric Antigen Receptor (CAR) T Cell Therapy — 0; 0; 1; 0 Participants

Primary: Number of Patients With Confirmed Objective Status of Complete Response (CR), Complete Clinical Response (CCR), Nodular Partial Response (nPR), or Partial Response (PR)…

Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014

Primary: Number of Participants With Adverse Events — 20 participants

Primary: Complete Response Rate — 83 percentage of participants

Primary: Survival at 1 Year After Transplantation — 10; 6 participants

Primary: 3-Year Event-Free Survival (EFS) — 68 Participants

Primary: Treatment Success and Feasibility of Autologous Activated T-cells Infusion, Determined by Number of Participants That Achieved Target-Activated T-cell Dose Without DLT…

Primary: Best Overall Response Rate (ORR) — 6; 0; 1; 0 Participants